approval · primary record
DENOSUMAB-ADET
2 approval events · latest 2026-09-29
| Agency | FDA |
|---|---|
| Submission type | BLA |
| Latest action | 2026-09-29 |
| Approval events | 2 |
| Brand | PONLIMSI |
| Sponsor | TEVA PHARMACEUTICALS, INC. |
| Route | SUBCUTANEOUS |
Approval history
2 actions on record. The drug is the stable record; each action below is an event with its own date, so this URL keeps working as new actions arrive.
| Date | Agency | Type | Brand | Sponsor | Route |
|---|---|---|---|---|---|
| 2026-09-29 | FDA | BLA | PONLIMSI | TEVA PHARMACEUTICALS, INC. | SUBCUTANEOUS |
| 2026-09-25 | FDA | BLA | DEGEVMA | TEVA PHARMACEUTICALS, INC. | SUBCUTANEOUS |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-30T00:30:27.977Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: approval:denosumab-adet
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Denosumab-Adet · compound